duocarmycin sa

Duocarmycin SA is an extremely potent cytotoxic agent and antitumor antibiotic that induces sequence-selective alkylation of duplex DNA, with an IC50 of 10 pM. It demonstrates synergistic cytotoxicity against glioblastoma multiforme (GBM) cells when combined with proton radiation in vitro.

Seco-Duocarmycin SA is a highly potent DNA alkylator used as an ADC cytotoxin.

Mal-PEG4-VC-PAB-DMEA-Seco-Duocarmycin SA is an antibody-drug conjugate linker, integrating the antitumor antibiotic Duocarmycin SA via the Mal-PEG4-VC-PAB-DMEA-Seco linker, aimed at targeted cancer therapy.

Anti-CCL2 (Carlumab)-MC-Vc-PAB-DMEA-PEG2-Duocarmycin SA is an antibody-drug conjugate (ADC) composed of the humanized anti-CCL2 (chemokine ligand 2) antibody Carlumab, linked with the MC-Vc-PAB-DMEA-PEG2 connector and the DNA alkylator Duocarmycin SA. This compound is utilized in cancer research.

Duocarmycin SA intermediate-2 is an intermediary compound in the synthesis of the antibiotic Duocarmycin SA. It can induce sequence-selective alkylation of double-stranded DNA (alkylation) and exhibits synergistic anticancer cytotoxicity when combined with proton radiation.

Mal-PEG4-VC-PAB-DMEA-duocarmycin SA is a thiol-reactive Drug-linker. Duocarmycin SA is a highly effective and orally active cytotoxic agent that can be used in the synthesis of antibody-drug conjugates (ADCs).

DBCO-PEG4-VC-PAB-DMEA-Duocarmycin SA is a click-reactive Drug-linker that contains a DBCO group and can undergo strain-promoted acylnitridation addition reaction (SPAAC) with molecules containing azide groups. Duocarmycin SA is a highly effective and orally active cytotoxic agent. DBCO-PEG4-VC-PAB-DMEA-Duocarmycin SA can be used in the synthesis of antibody-drug conjugates (ADC).

(S)-Seco-Duocarmycin SA is a DNA alkylating agent and antibiotic with potent antitumor activity that can be used to synthesize ADC compounds.